Head-To-Head Contrast: Aileron Therapeutics (NASDAQ:ALRN) and Altamira Therapeutics (NASDAQ:CYTO)

Aileron Therapeutics (NASDAQ:ALRN) and Altamira Therapeutics (NASDAQ:CYTO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Aileron Therapeutics and Altamira Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aileron Therapeutics	0	0	1	1	3.50
Altamira Therapeutics	0	0	0	0	0.00

Aileron Therapeutics presently has a consensus target price of $19.00, suggesting a potential upside of 0.00%. Given Aileron Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Aileron Therapeutics is more favorable than Altamira Therapeutics.

Risk & Volatility

Aileron Therapeutics has a beta of 2.24, meaning that its stock price is 124% more volatile than the S&P 500. Comparatively, Altamira Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500.

Profitability

This table compares Aileron Therapeutics and Altamira Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aileron Therapeutics	N/A	-74.08%	-27.93%
Altamira Therapeutics	N/A	N/A	N/A

Institutional and Insider Ownership

90.9% of Aileron Therapeutics shares are owned by institutional investors. Comparatively, 1.9% of Altamira Therapeutics shares are owned by institutional investors. 5.1% of Aileron Therapeutics shares are owned by insiders. Comparatively, 13.0% of Altamira Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Aileron Therapeutics and Altamira Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aileron Therapeutics	N/A	N/A	-$15.73 million	($3.12)	N/A
Altamira Therapeutics	$320,000.00	3.19	-$4.31 million	N/A	N/A

Altamira Therapeutics has higher revenue and earnings than Aileron Therapeutics.

Summary

Aileron Therapeutics beats Altamira Therapeutics on 6 of the 11 factors compared between the two stocks.

About Aileron Therapeutics

Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.

About Altamira Therapeutics

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.